Diagnosis and Management of Tumor-induced Osteomalacia: Perspectives From Clinical Experience
Open Access
- 2 June 2021
- journal article
- research article
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 5 (9), bvab099
- https://doi.org/10.1210/jendso/bvab099
Abstract
Purpose: Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome of abnormal phosphate and vitamin D metabolism caused by typically small endocrine tumors that secrete fibroblast growth factor 23 (FGF23). TIO is characterized clinically by progressive musculoskeletal pain, fatigue, proximal muscle weakness, and multiple fractures, leading to long-term disability. Misdiagnosis and delayed diagnosis are common because of the nonspecific symptoms, and several years may elapse before patients receive an accurate diagnosis and appropriate treatment. Thus, it is vital that awareness of the appropriate recognition and management of TIO is increased among healthcare professionals who may encounter patients with suspected TIO. Methods: A roundtable meeting was held on 10 January 2020 in Dallas, TX, USA, to gather perspectives on the diagnosis and treatment of TIO. The following topics were considered: clinical presentation, patient history, differential diagnosis, laboratory assessment, imaging, venous sampling, and treatment. Results: This report provides a summary of our collective experiences in the management of TIO. Main conclusions: Laboratory tests are mandatory to expedite TIO diagnosis and should include measurement of fasting serum phosphorus, renal phosphate reabsorption, serum 1,25-dihydroxyvitamin D, and serum FGF23 levels. Functional and anatomical imaging are essential to locate the FGF23-secreting tumor(s) causing TIO. Surgical resection is often a curative treatment when the tumor can be localized; however, better management of patients who cannot be operated on with targeted therapies is needed. Further efforts to increase awareness of TIO within the medical community, and education on recommended diagnostic and treatment pathways are required to improve the management of this debilitating disease.Keywords
Funding Information
- Ultragenyx Pharmaceutical Inc.
- Kyowa Kirin International plc
This publication has 65 references indexed in Scilit:
- Tumor localization and biochemical response to cure in tumor-induced osteomalaciaJournal of Bone and Mineral Research, 2013
- Iron Modifies Plasma FGF23 Differently in Autosomal Dominant Hypophosphatemic Rickets and Healthy HumansJournal of Clinical Endocrinology & Metabolism, 2011
- Tumor-induced osteomalaciaEndocrine-Related Cancer, 2011
- Radiation Risk From Medical ImagingMayo Clinic Proceedings, 2010
- Selective venous catheterization for the localization of phosphaturic mesenchymal tumorsJournal of Bone and Mineral Research, 2010
- Clinical utility of systemic venous sampling of FGF23 for identifying tumours responsible for tumour‐induced osteomalaciaJournal of Internal Medicine, 2010
- Treatment of Recurrent Intracranial Hemangiopericytoma with SRC-Related Tyrosine Kinase Targeted Therapy: A Case ReportCase Reports in Oncology, 2010
- Exposure to Low-Dose Ionizing Radiation from Medical Imaging ProceduresThe New England Journal of Medicine, 2009
- Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: Proposal of diagnostic criteria using FGF23 measurementBone, 2008
- Phosphaturic mesenchymal tumors. A polymorphous group causing osteomalacia or ricketsCancer, 1987